BioNTech Results Presentation Deck

Expected Pipeline Milestones in 2022 (2 of 2) Infectious Diseases • Shingles vaccine ¹ ● Tuberculosis vaccine2 HSV 2 vaccine Malaria vaccine ● ● Oncology BNT141 - RiboMab, solid tumors. • BNT142 - RiboMab, solid tumors BNT116 - Fixvac in combination w/Libtayo, NSCLC ● Up to 7 First-in-Human Trial Starts 35 HSV 2, herpes simplex virus type 2; FPD, first patient dosed; NSCLC, non-small cell lung cancer 1 Partnered with Pfizer 2 Partnered with Bill and Melinda Gates Foundation Timing 2H 2H 2H 2H ✓ FPD in January 1H 2H BIONTECH

View entire presentation